A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice

F. Errico, V. D'Argenio, F. Sforazzini, F. Iasevoli, M. Squillace, G. Guerri, F. Napolitano, T. Angrisano, A. Di Maio, S. Keller, D. Vitucci, A. Galbusera, L. Chiariotti, A. Bertolino, A. De Bartolomeis, F. Salvatore, A. Gozzi, A. Usiello

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Pharmacogenetics may allow for a personalized treatment, but a combination with clinical variables may further enhance prediction. In particular, in the present paper, we investigated early partial improvement (EPI) defined as 20% or more improvement by rating scales 2weeks after treatment, in combination with selected gene variants as a predictor of treatment outcome in patients with major depressive disorder. Two randomized controlled trials with 168 Japanese depressed patients were used. A stepwise multiple linear regression model with HAM-D score change at week 6 as the dependent variable and genotypes, EPI, baseline HAM-D score, age and sex as independent variables was performed in paroxetine, fluvoxamine and milnacipran, respectively, to estimate the prediction of HAM-D change at week 6. In the paroxetine sample, only EPI (P

Original languageEnglish
Article numbere512
JournalTranslational Psychiatry
Volume5
Issue number2
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

D-Aspartate Oxidase
Phencyclidine
Paroxetine
Linear Models
Schizophrenia
Fluvoxamine
Pharmacogenetics
Major Depressive Disorder
Randomized Controlled Trials
Genotype
Therapeutics
Genes

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Cellular and Molecular Neuroscience

Cite this

Errico, F., D'Argenio, V., Sforazzini, F., Iasevoli, F., Squillace, M., Guerri, G., ... Usiello, A. (2015). A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice. Translational Psychiatry, 5(2), [e512]. https://doi.org/10.1038/tp.2015.2

A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice. / Errico, F.; D'Argenio, V.; Sforazzini, F.; Iasevoli, F.; Squillace, M.; Guerri, G.; Napolitano, F.; Angrisano, T.; Di Maio, A.; Keller, S.; Vitucci, D.; Galbusera, A.; Chiariotti, L.; Bertolino, A.; De Bartolomeis, A.; Salvatore, F.; Gozzi, A.; Usiello, A.

In: Translational Psychiatry, Vol. 5, No. 2, e512, 01.01.2015.

Research output: Contribution to journalArticle

Errico, F, D'Argenio, V, Sforazzini, F, Iasevoli, F, Squillace, M, Guerri, G, Napolitano, F, Angrisano, T, Di Maio, A, Keller, S, Vitucci, D, Galbusera, A, Chiariotti, L, Bertolino, A, De Bartolomeis, A, Salvatore, F, Gozzi, A & Usiello, A 2015, 'A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice', Translational Psychiatry, vol. 5, no. 2, e512. https://doi.org/10.1038/tp.2015.2
Errico, F. ; D'Argenio, V. ; Sforazzini, F. ; Iasevoli, F. ; Squillace, M. ; Guerri, G. ; Napolitano, F. ; Angrisano, T. ; Di Maio, A. ; Keller, S. ; Vitucci, D. ; Galbusera, A. ; Chiariotti, L. ; Bertolino, A. ; De Bartolomeis, A. ; Salvatore, F. ; Gozzi, A. ; Usiello, A. / A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice. In: Translational Psychiatry. 2015 ; Vol. 5, No. 2.
@article{5e823b30ab894390aa63993b7227b74f,
title = "A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice",
abstract = "Pharmacogenetics may allow for a personalized treatment, but a combination with clinical variables may further enhance prediction. In particular, in the present paper, we investigated early partial improvement (EPI) defined as 20{\%} or more improvement by rating scales 2weeks after treatment, in combination with selected gene variants as a predictor of treatment outcome in patients with major depressive disorder. Two randomized controlled trials with 168 Japanese depressed patients were used. A stepwise multiple linear regression model with HAM-D score change at week 6 as the dependent variable and genotypes, EPI, baseline HAM-D score, age and sex as independent variables was performed in paroxetine, fluvoxamine and milnacipran, respectively, to estimate the prediction of HAM-D change at week 6. In the paroxetine sample, only EPI (P",
author = "F. Errico and V. D'Argenio and F. Sforazzini and F. Iasevoli and M. Squillace and G. Guerri and F. Napolitano and T. Angrisano and {Di Maio}, A. and S. Keller and D. Vitucci and A. Galbusera and L. Chiariotti and A. Bertolino and {De Bartolomeis}, A. and F. Salvatore and A. Gozzi and A. Usiello",
year = "2015",
month = "1",
day = "1",
doi = "10.1038/tp.2015.2",
language = "English",
volume = "5",
journal = "Translational Psychiatry",
issn = "2158-3188",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice

AU - Errico, F.

AU - D'Argenio, V.

AU - Sforazzini, F.

AU - Iasevoli, F.

AU - Squillace, M.

AU - Guerri, G.

AU - Napolitano, F.

AU - Angrisano, T.

AU - Di Maio, A.

AU - Keller, S.

AU - Vitucci, D.

AU - Galbusera, A.

AU - Chiariotti, L.

AU - Bertolino, A.

AU - De Bartolomeis, A.

AU - Salvatore, F.

AU - Gozzi, A.

AU - Usiello, A.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Pharmacogenetics may allow for a personalized treatment, but a combination with clinical variables may further enhance prediction. In particular, in the present paper, we investigated early partial improvement (EPI) defined as 20% or more improvement by rating scales 2weeks after treatment, in combination with selected gene variants as a predictor of treatment outcome in patients with major depressive disorder. Two randomized controlled trials with 168 Japanese depressed patients were used. A stepwise multiple linear regression model with HAM-D score change at week 6 as the dependent variable and genotypes, EPI, baseline HAM-D score, age and sex as independent variables was performed in paroxetine, fluvoxamine and milnacipran, respectively, to estimate the prediction of HAM-D change at week 6. In the paroxetine sample, only EPI (P

AB - Pharmacogenetics may allow for a personalized treatment, but a combination with clinical variables may further enhance prediction. In particular, in the present paper, we investigated early partial improvement (EPI) defined as 20% or more improvement by rating scales 2weeks after treatment, in combination with selected gene variants as a predictor of treatment outcome in patients with major depressive disorder. Two randomized controlled trials with 168 Japanese depressed patients were used. A stepwise multiple linear regression model with HAM-D score change at week 6 as the dependent variable and genotypes, EPI, baseline HAM-D score, age and sex as independent variables was performed in paroxetine, fluvoxamine and milnacipran, respectively, to estimate the prediction of HAM-D change at week 6. In the paroxetine sample, only EPI (P

UR - http://www.scopus.com/inward/record.url?scp=84927722951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927722951&partnerID=8YFLogxK

U2 - 10.1038/tp.2015.2

DO - 10.1038/tp.2015.2

M3 - Article

C2 - 25689573

AN - SCOPUS:84927722951

VL - 5

JO - Translational Psychiatry

JF - Translational Psychiatry

SN - 2158-3188

IS - 2

M1 - e512

ER -